Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Diamond Biotechnology Co's FCF Yield % or its related term are showing as below:
ROCO:6815'
s FCF Yield % Range Over the Past 10 Years
Min: -7.42 Med: 0.36 Max: 9.89
Current: -0.27
During the past 9 years, the highest FCF Yield % of Diamond Biotechnology Co was 9.89%. The lowest was -7.42%. And the median was 0.36%.
ROCO:6815's FCF Yield % is ranked better than 50.99% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: -0.4
vs ROCO:6815: -0.27
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Diamond Biotechnology Co FCF Yield % Related Terms
Diamond Biotechnology Co FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6815 vs ABT, SYK, MDT: FCF Yield % Comparison
For the Medical Devices subindustry, Diamond Biotechnology Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamond Biotechnology Co FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Diamond Biotechnology Co's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Diamond Biotechnology Co's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamond Biotechnology Co (ROCO:6815) has a FCF Yield % of -0.27 as of Jul. 18, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Diamond Biotechnology Co and its competitors. According to the industry distribution chart, Diamond Biotechnology Co ranks #419 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 49%.
Is Diamond Biotechnology Co's FCF Yield % too high?
Diamond Biotechnology Co's current FCF Yield % is -0.27. Based on the distribution chart, Diamond Biotechnology Co ranks #419 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Diamond Biotechnology Co has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Diamond Biotechnology Co's FCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Diamond Biotechnology Co ranks #419 out of 855 companies for FCF Yield %. This puts Diamond Biotechnology Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Diamond Biotechnology Co and its competitors. Diamond Biotechnology Co's current FCF Yield % is -0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamond Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Diamond Biotechnology Co (ROCO:6815) is currently considered Possible Value Trap. The stock's GF Value™ is NT$48.10, compared to a current price of NT$29.70 — trading 38.3% below its estimated fair value. The current FCF Yield % is -0.27. Diamond Biotechnology Co's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Diamond Biotechnology Co (ROCO:6815), the current FCF Yield % is -0.27 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamond Biotechnology Co (ROCO:6815) Overvalued in 2026?
Based on GuruFocus' analysis, Diamond Biotechnology Co stock appears to be undervalued.
The current stock price of NT$29.70 is trading 38.3% below its estimated GF Value™ of NT$48.10.
GuruFocus considers Diamond Biotechnology Co to be Possible Value Trap.
Key valuation signals for ROCO:6815:
FCF Yield %: -0.27
GF Value™: NT$48.10 vs. price of NT$29.70 (38.3% below fair value)
No single metric tells the full story. See the ROCO:6815 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamond Biotechnology Co Ltd is engaged in the research and development of medical equipment, and medical consumables. It also manufactures and sells medical beauty-level skincare products.
80GF Score
Get the complete analysis for ROCO:6815
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6815 has been successfully added to your 
